Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity. It is being developed by Orexigen Therapeutics. It has undergone phase 2 tests and is waiting for phase 3 testing to commence. The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments. When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.
Empatic was called Excalia before its name was changed.
|This drug article relating to the nervous system is a stub. You can help World Heritage Encyclopedia by expanding it.|